The study, a joint effort bringing together doctors from Taiwan and the United States, set out to develop a clinical prediction model superior to the current benchmark (tumor size and the effect on lymph nodes) for the recurrence of breast cancer in patients who have had their breast removed and undergone radiation therapy. Their prediction model takes into account five different risk factors when assessing a patient's chances of having their cancer return. They include, status of the lymph nodes near the armpit, how well the patient is accepting estrogen boosts, how many lymph nodes were affected, age at diagnosis and primary tumor size.
The doctors found that the prognostic score and predictive index are useful in estimating recurrence in breast cancer patients after mastectomy and for approximating the benefits of radiation therapy. Doctors would then evaluate these factors to determine whether the patients had a low, intermediate or high risk of the cancer returning. Patients with a high risk of the cancer returning would need to undergo a course of radiation therapy to keep the cancer at bay, while those in the lower risk group were able to safely forgo the additional treatment.
"This prediction model is important because identifying the higher risk patients sooner will allow doctors to more aggressively treat those cancers, in the hopes of giving patients a higher chance for a cure," said Skye Hongiun Cheng, M.D., lead author of the study and a radiation oncologist at Koo Foundation Sun Yat-Sen Cancer Center in Taipei, Taiwan.
For more information on radiation therapy for breast cancer, please visit www.rtanswers.org. To arrange an interview with Dr. Cheng or for a copy of "Prognostic Index Score and Clinical Prediction Model of Local Regional Recurrence After Mastectomy in Breast Cancer Patients," please contact Nick Lashinsky at firstname.lastname@example.org or 1-800-962-7876.
ASTRO is the largest radiation oncology society in the world, with more than 8,500 members who specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, biology and physics, the Society is dedicated to the advancement of the practice of radiation oncology by promoting excellence in patient care, providing opportunities for educational and professional development, promoting research and disseminating research results and representing radiation oncology in a rapidly evolving socioeconomic healthcare environment.